Biotech Stock Pops After Surprise Deal!

Repare Therapeutics just scored a big payday—$267 million potential—from a licensing deal with Debiopharm for a new cancer drug. Their stock, which was in the dumps, shot up over 20% after hours. Why the buzz? Debiopharm’s taking over the heavy lifting on trials, so Repare gets to sit back and collect milestone payments and royalties if things go well. Retail traders are piling in, hoping this underdog keeps winning. If you like a little risk with your coffee, this is one to watch! #Business #Industry #StockMarket